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Chronic Obstructive Pulmonary Disease (COPD) is defined as a disease characterized by persistent, progressive airflow limitation.
Recent studies have underlined that COPD is correlated to many systemic manifestations, probably due to an underlying pattern
of systemic inflammation. In COPD fractional exhaled Nitric Oxide (FeNO) levels are related to smoking habits and disease
severity, showing a positive relationship with respiratory functional parameters. Moreover FeNO is increased in patients with
COPD exacerbation, compared with stable ones. In alpha-1 antitrypsin deficiency, a possible cause of COPD, FeNO levels may
be monitored to early detect a disease progression. FeNO measurements may be useful in clinical setting to identify the level of
airway inflammation, per se and in relation to comorbidities, such as pulmonary arterial hypertension and cardiovascular diseases,
either in basal conditions or during treatment. Finally, some systemic inflammatory diseases, such as psoriasis, have been associated
with higher FeNO levels and potentially with an increased risk of developingCOPD. In these systemic inflammatory diseases, FeNO
monitoring may be a useful biomarker for early diagnosis of COPD development.
1. Introduction
As is well known, chronic obstructive pulmonary disease
(COPD) is simply considered a lung disease characterised
by the presence of fixed and progressive airflow limitation
derived from airway inflammation/remodelling associated
with parenchymal destruction so-called pulmonary emphy-
sema. However, in most of COPD patients the disease
coexists with several other systemic manifestations which
can make health-related quality of life worse and increase
mortality [1]. Thus, COPD could no longer be defined as a
disease restricted to the lung but might be considered part
of a complex chronic systemic disease previously defined as
“chronic systemic inflammatory syndrome” [2].
The best-recognised comorbidities in COPD include
lung cancer, cardiovascular diseases, malnutrition involv-
ing primarily the loss and dysfunction of skeletal muscles,
osteoporosis, anaemia, diabetes, increased gastroesophageal
reflux, metabolic syndrome, obstructive sleep apnoea, de-
pression, and anxiety. Comorbidities can be classified in
conditions that share pathogenetic mechanisms with COPD
(e.g., smoking-related diseases such as ischemic heart disease
and lung cancer), conditions that complicate COPD (such
as osteoporosis and sarcopenia), and conditions that are
simply associated with COPD for epidemiologic reasons (like
glaucoma and obstructive sleep apnoea) [3].
In COPD patients, the high frequency of concurrent
diseases may be largely explained by the old age of the
majority of patients and by cigarette smoke exposure, the
major risk factor for COPD, many other chronic diseases,
and certain cancers. Smoking triggers a local inflammatory
response throughout the whole tracheobronchial tree, and
pathologic changes, a characteristic of COPD, are found in
the proximal large airways, peripheral small airways, lung
parenchyma, and pulmonary vasculature [4]. Apart from
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these local effects, smoking may significantly contribute to
or cause systemic inflammation including the stimulation
of the hematopoietic system with polymorph nuclear leuko-
cytes release, the generation of systemic oxidative stress,
and the endothelial dysfunction of peripheral vessels [4].
These systemic effects due to smoking may account for the
frequent concurrent presence of other chronic illnesses such
as cardiovascular diseases and metabolic disorders in COPD
patients [4].
Furthermore, one-half of all people aging more than 65
years have at least three chronic medical conditions, and
aging itself is associated with a chronic low-grade inflamma-
tory status [5]. Thus, the theory that systemic inflammation
is the common driver of chronic diseases would explain the
high prevalence of chronic diseases with increasing age, so-
called “inflammaging” [5]. Concerning the observed associ-
ations between COPD and its comorbidities, there are two
possible explanations: the systemic “spill-over” of the inflam-
matory and reparatory events occurring in COPD lungs with
a central role of the disease in the process and the “sys-
temic” inflammatory state due tomultiple organ compromise
which includes also COPD pulmonary manifestations [2, 6].
Patients with COPD show systemic inflammation, especially
related to disease severity and exacerbations, that can be
measured as increment of circulating cytokines (IL-6, TNF-
𝛼), chemokines (IL-8), and acute phase proteins (C-reactive
protein (CRP) and surfactant protein D) or abnormalities in
circulating cells [7]. One of the most important pathogenetic
mechanisms of COPD is oxidative stress associated with
inflammatory cellular infiltration (macrophages, neutrophils,
and lymphocytes CD8) that in conjunction with an altered
release of endogenous nitric oxide (NO) may provoke the
formation of “nitrative stress” [6].
2. Nitric Oxide and COPD
Endogenous nitric oxide (NO) is a gaseous signaling
molecule produced by residential and inflammatory cells
in both large and peripheral airways/alveoli. NO plays an
important role in regulating airway and vascular function and
is generated by three isoforms of NO synthases (neuronal
NOS (nNOS, NOS1), endothelial NOS (eNOS, NOS3), and
inducible NOS (iNOS, NOS2)) with different expression and
pathophysiologic roles in the airways. In particular, iNOS
is not constitutively expressed but is induced by several
stimuli including endogenous mediators (chemokines and
cytokines) and exogenous factors (bacterial toxins, viral
infection, allergens, environmental pollutants, etc.) [8]. NO is
generated by the conversion of L-arginine to L-citrulline and
during inflammation, due to iNOS induction, large amounts
ofNOare producedwhichmay exert proinflammatory effects
[9].
Corticosteroids directly suppress iNOS in rodent cells but
do not directly inhibit iNOS expression in human airway
epithelial cells [10]. The increase in NO in exhaled breath in
asthma is presumed to originate from increased iNOS expres-
sion in the respiratory tract, although cNOS isoforms (nNOS
and eNOS) may also contribute. Increased iNOS expression
is found in airway epithelial cells of patients with asthma and
is reduced by inhaled corticosteroids [11]. Increased iNOS
expression is found in central and small airways and in
peripheral lung of COPD patients [12, 13]; however, there
was no effect of high-dose ICS on exhaled nitric oxide at
both airway and alveolar compartments [14] suggesting that
probably in COPD iNOS is not the main source of NO. In
other studies, selective inhibitors of iNOS reduce FeNO in
asthmatic patients and also in normal subjects [15–17] but
have less effect on COPD patients. In a recent study, Brindicci
et al. showed that nNOS expression and activity are increased
in COPD according to disease severity suggesting that in
these patients the increased peripheral NO may be derived
from nNOS [12].
Oxidative stress generates superoxide anions and in
combination with NO may result in the formation of the
highly reactive species peroxynitrite, which is increased in
exhaled breath condensate and airway mucosa of COPD
patients [13–18] and removes NO from the gaseous phase so
that its concentration in the airways is reduced when there is
a high level of oxidative stress, as in COPD patients [10].
3. FeNO and COPD
FeNO measurements have been considered a surrogate for
eosinophilic airway inflammation, especially in asthma. In
most mild asthmatics, high FeNO at 50mL s−1 (>45 ppb)
has been regarded as a marker for steroid responsiveness
[19, 20] including improvement in spirometry and airway
hyperresponsiveness [21].The ATS clinical practice guideline
for exhaled nitric oxide in asthma concluded that add-
on FeNO monitoring provides potential easier detection of
eosinophilic airway inflammation and likelihood of corticos-
teroid responsiveness [22].
FeNO levels in COPD are conflictual [8], but it seems that
smoking habits and disease severity are the most important
factors influencing exhaled NO levels in these patients [23].
Current smokers [24] and severe COPD (particularly in
combination with cor pulmonale) [25] show lower levels of
exhaled NO than ex-smokers and mild/moderate COPD
(Table 1). Increased exhaled NO levels have been reported
in hospitalized patients during an exacerbation of COPD
(Table 1) [26]. Interestingly, exhaled NO levels returned to
control values only months after discharge of those steroid-
treated patients, suggesting different inflammatory mecha-
nisms in COPD compared with the highly steroid-sensitive
asthmatics [26].
In COPD patients, the magnitude of the NO signal is
considerably less than in asthma and, most importantly, the
major causative agent, cigarette smoke, dramatically masks
any tendency towards a disease related rise in exhaled NO
levels. This may have consequences not only for monitoring
patients with COPD, but also for the natural history and
prognosis of the disease. The positive relationship between
exhaledNO levels and FEV
1
is in keeping with the hypothesis
that endogenous NO represents an important protective
mechanism. This could be particularly relevant in patients
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with COPD who may require local NO release for antimi-
crobial host defence or preservation of ventilation/perfusion
matching within the lung [23].
Several studies [27–31] showed that elevated FeNO in
COPDmay also be a variable signal for increased spirometric
response to ICS. Moreover FeNO is increased in patient
with COPD exacerbation, compared to the levels observed in
patients with stable COPD [32]. In a recent study, Soter at al.
demonstrated that FeNO is a good biomarker of eosinophilic
inflammation in COPD patients with exacerbation [33].
In conclusion, in COPD the role of FeNO monitoring to
therapeutic intervention is still unclearwith respect to clinical
relevance in particular because of the absence of randomized,
double blind, control studies.
3.1. FeNO in Alpha-1 Antitrypsin (AAT) Deficiency. Alpha-
1 antitrypsin (AAT) deficiency is a genetic disorder due to
homozygosity or heterozygosity for the protease inhibitor
(Pi) Z allele, and these two genetic phenotypes are, respec-
tively, characterized by a severe reduction (PiZZ) and a lower
reduction (PiMZ) of plasma levels of AAT than in normal
subjects. The homozygotic form of the disease is considered
to be an important risk factor for developing COPD [34].
Severe AAT deficiency (PiZZ) is characterized by lower
FeNO level (Table 1) compared to healthy nonsmokers and
COPD patients, which is correlated to the pulmonary func-
tion impairment which is a characteristic of this kind of
patients [35, 36].While, PiMZ subjects show increased FeNO
levels (Table 1) compared to COPD patients and healthy
controls [37] and FeNO levels are related to the reduced
concentration of AAT in plasma [38]. In these patients FeNO
measurement may be very important to monitor a possible
progression of airways inflammation to COPD.
3.2. FeNO in Pulmonary Arterial Hypertension. Pulmonary
arterial hypertension (PAH) is characterized by an elevation
of the pulmonary arterial pressure and an increased pul-
monary vascular resistance, leading to decline in cardiopul-
monary function and premature death [39].
PAH is commonly caused by an underlying pulmonary or
systemic disease, whilst idiopathic PAH (IPAH) is referred to
PAH when diagnosed in the absence of an identifiable cause
or disease.
IPAH is the most studied form of PAH, characterized
by endothelial and smooth muscle cell proliferation, medial
hypertrophy, and thrombosis in situ [40].The elevated vascu-
lar resistance probably is due to an imbalance between local
vasodilators and vasoconstrictors, associated with cellular
proliferation and vascular remodeling. NO is one of the
important pathophysiologic mediators of pulmonary vascu-
lar resistance [41, 42]. NO produced in the upper and lower
airways by NOS2 is able to affect the pulmonary vascular
tone together with the NO produced by NOS3 in the vascular
endothelium [43]. Once produced NO is highly diffusible
and activates soluble guanylate/cyclase in pulmonary vascu-
lar smooth muscle cells to produce guanosine 39-59-cyclic
monophosphate, inducing vascular smooth muscle relax-
ation and then vasodilation [44]. Patients with PAH show low
Table 1: Trend of FeNO levels in COPD and related comorbidities.
Disease/condition FeNO levels
Smoking habit ↓
Severe COPD ↓
Stable COPD =
Exacerbation of COPD ↑
AAT deficiency PiZZ ↓
AAT deficiency PiMZ ↑
PAH ↓
Systemic sclerosis ↑
Decompensated HF ↑
After exercise in stable HF ↑
Atherosclerosis ↓
Psoriasis ↑
↑: >20 ppb; =: 10–20 ppb; ↓: <10 ppb.
FeNO values (Table 1) [44, 45]. Patients with PAH also show
lower concentrations of NO than normal in the BAL fluid,
inversely related to the degree of pulmonary hypertension
[46]. Therefore, replacement of NO seems to work well
in treating PAH [42]. Phosphodiesterase type 5 inhibitors,
preventing the collapse of the NO effector molecule 39,59-
cyclic guanosine monophosphate, prolong NO mediated
vasodilatation [47, 48]. Prostacyclins and endothelin receptor
antagonists also are able to reduce the NO deficiency state in
patientswith PAH [49]. PAHpatientswho respond to therapy
show higher FeNO levels compared with those who do not
change their FeNO levels in response to therapy [47]. The
presence of reduced FeNO levels in patients with PAH and
the increase after treatment suggest that serial monitoring of
FeNO in these patients may be useful.
3.3. FeNO in Systemic Sclerosis (SSC) with Pulmonary Arte-
rial Hypertension. Systemic sclerosis (SSc) is a connective
tissue disorder of unknown etiology, characterized by a
multisystemic involvement, and that is often complicated
by pulmonary involvement [50], especially PAH with or
without interstitial lung disease (ILD) [51]. The mechanisms
underlying pulmonary involvement of SSc are unknown,
but endothelial changes, both morphological and functional,
may be pathogenetically important [52]. Moreover, in these
patients inflammation probably promotes the development
of pulmonary fibrosis [53]. NO can be implicated in the
pathogenesis of both PAH and ILD. In fact, NO plays an
important role in maintaining the low resistance of the
pulmonary circulation [54], so if basal production of NO
mediated by eNOS is low, it could promote vasoconstriction
and vascularwall thickening, bringing to PAH [55].Moreover
iNOS is stimulated by inflammatory cytokines [56]; the
presence of an inflammatory pattern, such as in SSc, is linked
to an increase of iNOS activation; and NO proinflammatory
and cytotoxic effects could promote ILD [57]. A recent
study investigated the value of FeNO in a group of 50 SSc
patients, with the diagnosis based on American Rheumatism
Association criteria [58], compared with 40 healthy subjects
[45]. The FeNO levels were higher in SSc patients than in
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control subjects (Table 1), and lower in patient with ILD
and/or PAH than in those without PAH, moreover there was
an inverse correlation between the severity of pulmonary
artery pressure and FeNO levels.
3.4. FeNO in Cardiovascular Diseases
3.4.1. Heart Failure. It has been hypothesized that NO pro-
vides an important role in heart failure (HF) in either the
pathogenesis or disease progression, although the precise role
played by NO is complex [59]. In particular, NO release
from the vascular endothelium in patients with heart failure
may help to maintain tissue perfusion by reducing the
vasoconstriction induced by various neurohumoral factors;
moreover NO is able to modulate cardiac contractility [59].
In patients with chronic HF, deregulated systemic NO
production due to endogenous inhibitors of NO synthases
such as asymmetric dimethylarginine (ADMA) has been
related to both systolic and diastolic dysfunction in addition
to poor long-term adverse outcomes [60].
Several studies in symptomatic HF patients at rest have
reported variable FeNO levels compared with normal control
subjects, and the results in literature are conflicting. Higher
levels of FeNO were observed in decompensated HF resting
(Table 1) compared with compensated and resting FeNO
decreased after lowering of left ventricular filling pressures
[61]. Higher FeNO levels have been observed after exercise in
stable chronic HF patients (Table 1) compared with control
subjects [62, 63].
Patients who fail to raise FeNO during exercise have been
related to a higher long-termmortality rate [64]. Accordingly
a potential role ofNOproduction as a compensatory response
to the increased pressure in the pulmonary venous circulation
has been hypothesized.
As mentioned above, several FeNO studies have shown
conflicting results regarding FeNO levels at rest and exercise.
These contradictory reports can probably be explained by
the difference in the populations studied and the use of
different techniques for FeNO analysis; moreover the type of
cardiomyopathy is rarely reported, and it can be hypothesized
that ischemic heart disease could be much different in terms
of NO production than idiopathic dilatative heart disease.
However, more recent reports seem to indicate that FeNO
levels increased after exercise in chronic compensated HF
patients [63]. This seems to be related to the degree of
pulmonary congestion and hypertension; probable increased
activity of pulmonary endothelial NO synthases appears in
response to improved flow, in the pulmonary vasculature
taking place during exercise, as a compensatory mechanism.
Consequently, higher FeNO may represent a compensatory
mechanism in response to high-flow conditions [65].
3.4.2. FeNO in Atherosclerosis and Cardiovascular Risk Fac-
tors. Endothelial NO seems to play a key role in the athero-
genic process platelet adhesion and aggregation, expression of
adhesion molecule and chemokine production, and inflam-
matory cell infiltration together with smooth muscle cell
migration and proliferation [66, 67].
This central balancing function of NO is hindered during
the atherosclerotic process, in which endothelial damage
causes the decline in bioactivity of endothelial nitric oxide
synthase and consequently impaired release of NO. Further-
more, ischemic heart disease (IHD) is characterized by a low-
grade systemic inflammation and associated with increased
oxidative stress; these factors enhance the inactivation of NO
at endothelial level in the arterial wall and could lead to
diminished systemic bioavailability of NO [68]. Therefore,
it is possible to hypothesize that, because NO production
is reduced and its inactivation increased in dysfunctional
atherosclerotic endothelium, atherosclerosis is inversely asso-
ciated with NO and FeNO (Table 1). Consequently a recent
paper [69] observed that two common atherosclerosis risk
factors, triglycerides serum levels and hemoglobin/A1c (a
marker of hyperglycaemic metabolism), were inversely asso-
ciated with FeNO levels in patients with IHD. This can
be explained by the reduced eNOS and the enhanced NO
degradation due to endothelial damage, characteristics of
atherosclerosis [69].
3.5. FeNO in Psoriasis. Psoriasis vulgaris is a multisystem
common dermatologic disease characterized by chronic
inflammatory pathogenesis [70]. The prevalence in adults
ranged from 0,91% in USA to 8,5% in Norway, while Italy
with the 2% was in the middle [71]. In literature, psoriasis
is also related to several comorbidities; these patients were
more likely to have diabetes, dyslipidemia, hypertension,
a history of myocardial infarction, inflammatory arthritis,
obesity, and metabolic syndrome than control groups [72].
Two recent studies evaluated the correlation between COPD
andpsoriasis, concluding that there is a significant correlation
between these two diseases. A large, population-based case-
control Israeli study by Dreiher et al. [73], including 12.502
psoriasis cases and 24.287 controls, demonstrated that the
prevalence of COPD was significantly higher in patients
with psoriasis (5,7% versus 3,6%, 𝑃 < 0,001 OR = 1,63).
Another study, conducted in Taiwan, on 10.480 patients with
psoriasis, underlined that psoriasis patients are at a greater
risk of developingCOPD,with significantly lowerCOPD-free
survival rates than the comparison cohort [74].
Recent developments described psoriasis pathophysi-
ology as mainly directed by Th1 and Th17 cells which
provoke a skin barrier dysfunction [75]. In literature, NO
production in skin cells was demonstrated physiologically
for several cytotypes such as keratinocytes, fibroblasts, and
melanocytes [76]. In psoriasic lesions, an overexpression of
iNOS is associated with a compensatory increase of arginase
1 enzyme which may reduce the NO availability [77]. On
the other hand, direct measurements of NO production in
psoriasic lesions did not find any evidence of a competitive
inhibition [78]. However, in psoriasis patient’s serum Gabr
et al. discovered an increase of NO levels that correlated
with the PASI (Psoriasis Area Severity Index) [79]. So this
studywas performed in order to detect if FeNOmeasurement
is useful in revealing earlier the pulmonary involvement in
this disease. The preliminary analysis about FeNO levels in
psoriasic patients pointed out the strong correlations between
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the active disease and an increased level of FeNO (Table 1),
suggesting a lung involvement.
4. Conclusions
New evidence concerning FeNO in relation to COPD and
the best-recognized comorbidities collectively highlights the
following potential roles of this biomarker in monitoring (1)
the stability of COPD; (2) the response to therapy in heart
failure and in PAH patients; (3) the possible progression to
COPD of other diseases like alpha-1 antitrypsin deficiency
and psoriasis. These latter aspects may be useful to integrate
the clinical evaluation of patients with COPD and comorbidi-
ties.
Since FeNO levels are strongly affected by cigarette
smoking and many COPD patients are current smokers,
the usefulness of FeNO measurement can be limited. In
COPD patients, the role of add-on FeNO monitoring to
therapeutic intervention is less clear with respect to clinical
benefits, especially in the absence of conclusive double-blind,
randomized, control studies. Therefore, routine monitoring
of FeNO in COPD is less established than in asthma as noted
in the recent ATS Clinical Guidelines.
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